Developing the UltraCAR-T® Platform to Expand Patient Access & Drive Scalable Manufacturing in Next-Generation Cell Therapy
- Designing multi-component, non-viral UltraCAR-T therapies to overcome biological and delivery limitations
- Reducing cost, time, and complexity to make precision medicine broadly accessible
- Demonstrating early Phase 2 efficacy, safety, and rapid treatment delivery in AML patients, enabled by overnight UltraCAR-T manufacturing